Vivo Opportunity, LLC
SEC-identified person · CIK 1728970 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Inmed Pharmaceuticals Inc. INM | Officer | filed 2026–2026 |
| Soleno Therapeutics INC SLNO | Officer | filed 2023–2025 |
| Terns Pharmaceuticals, Inc. TERN | Officer | filed 2021–2024 |
| Bolt Biotherapeutics, Inc. BOLT | Officer | filed 2021–2023 |
| IO Biotech, Inc. IOBT | Officer | filed 2023–2023 |
| Sierra Oncology, Inc. SRRA | Director | filed 2019–2022 |
| ALX Oncology Holdings INC ALXO | Officer | filed 2020–2020 |
| Crinetics Pharmaceuticals, Inc. CRNX | Officer | filed 2018–2020 |
| Kadmon Holdings, LLC kdmn | Officer | filed 2019–2019 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.